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(63.4%). Five studies were related to digestive cancers and other included peptic 
diseases, hernias and other. ConClusions: There was a considerable increase in 
publications of economic evaluations in Gastroenterology in Brazil, being mostly 
studies of drugs for treatment of viral hepatitis. The high cost of these treatments 
and increased of lawsuits seem to account for this increase.
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objeCtives: Liver transplantation is an effective treatment option for end-stage 
liver disease and acute liver failure, including patients with hepatitis C (HCV) and 
hepatitis B (HBV). Recent health technology assessments of treatments for HCV 
and HBV have relied on data from a large cohort study of transplanted patients to 
inform estimates of costs of liver tranplantations; however this was conducted in 
the 1990s. The overall aim of this study was to estimate the current cost of liver 
transplant for patients with HCV and HBV in the UK. Methods: Historical sum-
mary data from the original cohort study were updated to reflect current unit costs 
and key changes in clinical practice. Semi-structured interviews were conducted 
with experts and a computer-based user-interface was developed to elicit estimates 
of key resource use items. Uncertainty in the experts’ estimates was captured by 
eliciting probability distributions for each item from each expert. Updated unit costs 
were obtained from national sources. Data were analysed by phase of the transplant 
procedure. Results: The expert elicitation exercise included two hepatologists, 
three transplant surgeons and one liver transplant coordinator. Few patients with 
HBV are now being transplanted due to improvements in anti-viral treatments. 
Mean total costs for patients with HCV were £18,055 pre-transplantation, £64,452 
during the transplant phase and £36,009 in two years post-transplant. The average 
cost per transplanted patient with HCV from assessment to two years post-trans-
plant is £111,810. ConClusions: There have been some significant changes in 
clinical practice since the original study such as change in standard immunosup-
pressant therapy, more patients with co-morbidities being placed on the transplant 
waiting list, increased use of sub-optimal organs and reluctance to re-transplant 
patients with graft failure and recurrence of HCV.
GastroIntEstInaL DIsorDErs – Patient-reported outcomes & Patient  
Preference studies
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objeCtives: Prior to approval of telaprevir (TPV), the treatment for chronic hepatitis 
C virus (HCV) included peginterferon (P) weekly injections and ribavirin (R) orally 
twice daily. In 2011, TPV was approved for coadministration with P+R during the 
first 12 weeks. Though TPV improved viral clearance, it also increased the treat-
ment complexity by 2 pills given 3 times a day. The impact of increased regimen 
complexity on adherence is not well understood. This study compared treatment 
adherence over 24 weeks in HCV patients treated with TPV+PR compared to those 
on PR. Methods: Large US commercial and Medicaid health insurance claims 
databases were used to identify HCV patients initiating treatment with PR (pre-TPV 
[2007 to 2009]) or TPV+PR (post-TPV [2011 to 2013]). The index date was the date of 
HCV treatment initiation. Adherence was measured by medication possession ratio 
for all patients at 4 week intervals thru 24 weeks. Regression analyses adjusted for 
age, sex, comorbidities, liver disease severity, and pill count prior to HCV treat-
ment. Results: The study included 7,601 and 1,487 treated HCV patients in the 
commercial and Medicaid databases. Unadjusted and adjusted adherence was high 
for both cohorts throughout the study period (> 88% for Medicaid and > 82% for the 
commercial at 24 weeks). Adherence was not significantly different between the 
PR and T+PR cohorts at any time point in the Medicaid patients (88.9% [TPV+PR] 
and 90.5% [PR] at 24 weeks). Adherence was also similar between the cohorts in the 
commercial patients (82.7% [TPV+PR] and 83.2% [PR] at 24 weeks) but was statisti-
cally different at weeks 8 and 12, though not clinically meaningful. Age was the 
only factor consistently associated with adherence. ConClusions: Among HCV 
patients, adherence rates were high and were similar between the cohorts, despite 
the higher daily pill count for patients on TPV+PR.
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objeCtives: To estimate the utility scores for diarrheal children aged under 5 
years and their caregivers and to identify the influencing factors which affected 
on these. Methods: Hospitalized diarrheal children aged between 2 months and 
5 years and their caregivers at were recruited in this cross-sectional study at three 
hospitals in Phetchabun province. The EQ-5D instrument was used to collect the 
quality of life (QoL) data at the first date of admission. Quality of life of diarrheal 
children was measured as proxy report from caregiver while QoL of caregiver was 
measured as self-report. The raw data was converted to utility values using the Thai 
algorithm. The clinical severity of diarrheal children was rated using the Vesikari 
clinical severity scoring system. Stepwise multivariate linear regression was applied 
to explore the impact of the various factors on the utility value of children and 
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objeCtives: To conduct a cost-utility analysis of sofosbuvir for genotype 2 
chronic hepatitis C virus (HCV) infection in Japan. Methods: The Markov-model, 
“Sofosbuvir cost-effectiveness model”, which was constructed originally for similar 
study in UK, was modified and used for this analysis, while imputed data were 
replaced with Japanese data, as far as possible. Various health states, such as non-
cirrhotic hepatitis, sustained virological response (SVR), compensated cirrhosis, 
decompensated cirrhosis and hepatocellular carcinoma were incorporated to the 
model. Analyses were conducted for 4 scenarios, classified by treatment history 
(naive/experienced) and eligibility for interferon. Peg-interferon alpha with ribavirin 
was set as a comparator for those who were eligible for interferon. No treatment 
was selected for those who were not eligible for interferon. Probability of SVR was 
derived from clinical trials conducted in Japan. Other transition probabilities and 
utility scores of each health state were obtained from published data in Japan. 
Cost data for interferon-alpha and ribavirin were derived from national drug tariff 
(2014). For sofosbuvir, average European price was adopted since it was not yet 
approved in Japan. Other cost data, such as costs related to health states, were 
mainly obtained from claim data, provided by JMDC (Japan Medical Data Center). 
Inc. Time-horizon was set to lifetime. Costs and outcomes were discounted with 2% 
per annum, according to Japanese guideline. Results: For interferon-unsuitable 
patients, sofosbuvir was dominant to no-treatment. Sofosbuvir would save overall 
costs for JPY990,000 (USD9,900, JPY100= USD1) and prolonged 6.20QALY for treat-
ment naive patients. It would save JPY 837,000 and prolonged 6.08QALY for treat-
ment experienced group, For interferon-suitable patients, sofosbuvir would increase 
overall costs for JPY3,270,000 and prolonged 2.23QALY for treatment-naives. It would 
increase JPY1,551,000 and prolonged 2.36QALY for treatment-experienced. ICER 
were JPY1,470,000 and JPY657,000 per QALY gained, respectively. ConClusions: 
Sofosbuvir was considered to be cost-effective for treatment of genotype-2 HCV 
patients in Japan.
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objeCtives: In recent years a number of infections caused by Clostridium difficile 
has been significantly increasing. In Poland oral metronidazole constitutes the ther-
apy of choice of non-severe infection and first-recurrence, while oral vancomycin 
is recommended to be given in case of severe disease and subsequent recurrences. 
Fidaxomicin is a novel treatment for Clostridium difficile infections (CDI). The aim 
of this study was to perform a cost-utility analysis of fidaxomicin for the treatment 
of severe CDI compared to vancomycin. Methods: A meta-analysis of two ran-
domized clinical trials phase III comparing oral fidaxomicin and oral vancomycin 
in CDI was conducted. A Markov model was used to determine the cost-utility of 
fidaxomicin in patients with severe CDI. The cycle length was 10 days and the time 
horizon was 1 year. The patient entered the model in the severe CDI health state 
and was given either fidaxomycin or vancomycin for 10 days. The analysis was 
performed from the third-party payer perspective – the Polish National Health Fund. 
Only direct health care costs (drug costs, hospitalization) were included. Given the 
lack of formal utility measures for CDI, the utilities for the alternative health states 
described in the literature were adapted. Results: In the base case, fidaxomicin 
was dominant compared to vancomycin, resulting in cost savings of PLN 905 and 
an incremental QALY gain of 0.015. Fidaxomicin was associated with higher cost 
savings (PLN 30,883) assuming that patients with severe CDI would be hospital-
ized at intensive care unit. One-way sensitivity analyses revealed that fidaxomicin 
remained dominant even if considering marginal values of both antibiotics’ acqui-
sition cost. ConClusions: Fidaxomicin was dominant compared to vancomycin, 
generating additional QALYs with cost-savings in severe CDI patients in Poland.
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objeCtives: The aim of this study was to systematically review the economic 
assessment studies carried out in Brazil, published between January 1980 and 
December 2013, assessing the technologies studied, study types, the and tem-
poral evolution and quality. Methods: We systematically searched in MEDLINE 
(PubMed), EMBASE, LILACS, SciELO, NHS EED, HTA Database (CRD), BVS ECOS, 
SCOPUS, Web of Science, and SISREBRATS. We selected partial and full economic 
evaluation studies in gastroenterology, where at least one of the authors was affili-
ated to a Brazilian institution. Two authors performed study selection and data 
extraction independently. Disagreements were resolved through discussion or 
through consultation with a third reviewer. The study characteristics were sum-
marized in figures and summary tables. Results: Forty studies were included. The 
first studies were published in the 80s, but most occurred after 2000, with greater 
frequency in the last 4 years. Seventeen economic evaluations were incomplete 
(42.5%) and 23 complete (57.5%). In the 23 complete reviews, 11 (47.8%) studies 
were cost-utility analysis, 7 (30.4%) were cost-effectiveness analysis, 4 (17.4%) cost-
consequence analysis, and 1 (4.3%) cost-minimization analysis. The type of technol-
ogy evaluated was mainly medications in 25 studies (62.5%), 7 (17.5%) medical and 
surgical procedures, 3 (7.5%) medical and hospital equipment, 1 (2.5%) vaccines and 
4 (10%) evaluated more than one type of technology. When classified by disease, 22 
(55%) were studies on viral hepatitis, and in its most published after the year 2010 
